Aug. 01, 2017 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, announces the appointment ...

CRISPR Therapeutics' drug pipeline revolves around ... published Dec. 20 that it had parted ways with its head of R&D, Tony Ho. Even with the dramatic pullback across the last year of trading ...

Dr. Tony Ho is CRISPR's Head of Research and Development ... shows evidence of durable editing in bone marrow. Source: CRISPR Therapeutics corporate presentation August 2021.

Prior to CRISPR Therapeutics, Dr. Ho was SVP and Head ... is the solid cornerstone of Qihan's product innovation," said Dr. Tony Ho. "I am delighted to join Qihan's Board of Directors, and my ...

In the absence of Lundberg, Tony Ho, M.D., will oversee CRISPR ... that led to the creation of Casebia Therapeutics. Shares in CRISPR exited after-hours trading flat.

Heralding a new era in gene-editing medicines, Crispr is innovating a deep portfolio of therapeutics servicing ... that I was disappointed to see Dr. Tony Ho (i.e., the former Head of Research ...

Intellia and CRISPR Therapeutics both work in the field of gene editing. CRISPR Therapeutics just won regulatory approval for its first product, while Intellia recently entered late-stage ...

CRISPR Therapeutics (CRSP, Financials) stock rose 16.4% to $50.60 as of 10:10 a.m. GMT-5 on Friday, following an analyst upgrade. Citing pipeline advancements and possible catalysts, Evercore ISI ...